Primary mediastinal large B-cell lymphoma (PMBCL)

PMBCL often shows up as a fast-growing mass in the front of the chest. Symptoms such as cough, shortness of breath or a swollen face and neck usually build within a few weeks. A CT scan of the chest is usually the first test to look at the mass. A large mass can press on the airway or major veins, so prompt assessment matters.

The diagnosis needs a biopsy of the chest mass. Lab doctors (pathologists) look at the cells and test them for markers. PMBCL cells carry B-cell markers such as CD20. They often also carry CD23, MAL and PD-L1, and CD30 is weak when present. These tests matter because PMBCL can look like classic Hodgkin lymphoma, other large B-cell lymphomas or a mix of the two (mediastinal gray zone lymphoma). Each of these is treated differently.

A PET-CT scan shows how far the lymphoma has spread. Blood tests include blood counts and LDH, and HIV and hepatitis tests before treatment. Spread to the bone marrow or brain is uncommon at diagnosis. A PET-CT at the end of treatment also helps decide whether chest radiation is needed.

Initial treatment combines anti-CD20 therapy with chemotherapy. Regimen choice and whether to use mediastinal radiotherapy depend on the protocol, response and the need to limit late effects.

For relapsed or refractory disease, options include salvage chemoimmunotherapy, checkpoint inhibition and CAR-T therapy in eligible patients. A responding later relapse may be treated with high-dose chemotherapy and autologous stem cell rescue.

Allogeneic transplantation has a selected role after other treatments. Evidence and product indications often cover a broader large B-cell lymphoma group, so applicability to PMBCL and the individual treatment history must be checked.

Most people with PMBCL are cured by their first treatment. That treatment pairs the antibody rituximab with chemotherapy, sometimes followed by chest radiation. Results are better than for the more common large B-cell lymphoma that starts in lymph nodes. A clear end-of-treatment PET-CT scan is a strong good sign. In a large trial, people with a clear scan did very well whether or not they had radiation.

The harder path is for the 10% to 30% of people whose lymphoma does not respond or comes back, usually within the first year. For them, CAR-T cell therapy made from their own immune cells, immune checkpoint medicines or an own-cell stem cell transplant can bring another remission for some. A donor transplant is used only in selected cases.

Because many people are young adults, long-term health after treatment matters too. Chemotherapy and chest radiation can raise the later risk of heart disease and second cancers, so follow-up care watches for these.